Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
Subcutaneous administration of foslevodopa/foscarbidopa (PRODUODOPA®) in arm and thigh due to giant epigastric hernia: a case report.
Клинический случайПисьмо в редакциюНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Telarović Srđana, Čondić Jurjević Lucija
Аннотация
BACKGROUND: PRODUODOPA® is a combination of foscarbidopa and foslevodopa indicated for the treatment of motor fluctuations in patients with advanced Parkinson's disease when available combinations of peroral drugs have not given satisfactory results. The solution is administered via subcutaneous infusion, most frequently in the abdomen, using an infusion pump. The study results showed a significant effect on the reductions in off time and higher control of motor symptoms without troublesome dyskinesia.
CASE DESCRIPTION: A 61-year-old man on long-term oral therapy for Parkinson's disease presented with frequent wearing-off phenomenon, daily freezing episodes and occasional episodes of severe nocturnal akinesia. Due to giant epigastric hernia PRODUODOPA was administered subcutaneously in upper arm and thigh. The use of the pump resulted in an excellent therapeutic effect with a reduction in motor fluctuations and an improvement in the patient's quality of life. From the available medical literature, the use of the drug in the limb area has not been described so far.
CONCLUSION: PRODUODOPA can be administered subcutaneously in the area of the upper and lower extremities with just as good results as after subcutaneous infusion in abdomen.
CASE DESCRIPTION: A 61-year-old man on long-term oral therapy for Parkinson's disease presented with frequent wearing-off phenomenon, daily freezing episodes and occasional episodes of severe nocturnal akinesia. Due to giant epigastric hernia PRODUODOPA was administered subcutaneously in upper arm and thigh. The use of the pump resulted in an excellent therapeutic effect with a reduction in motor fluctuations and an improvement in the patient's quality of life. From the available medical literature, the use of the drug in the limb area has not been described so far.
CONCLUSION: PRODUODOPA can be administered subcutaneously in the area of the upper and lower extremities with just as good results as after subcutaneous infusion in abdomen.